Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Draft Honebuto Policy OK’ed by CEFP, Says Distinguish “Me Too” Drugs from Pioneering Meds
A draft of this year’s Basic Policy on Economic and Fiscal Management and Reform, dubbed honebuto, was given the nod by the government’s Council on Economic and Fiscal Policy (CEFP) on June 2, drawing a spate of opinions from panel…
To read the full story
Related Article
- Japan Cabinet Adopts 2017 Honebuto Policy
June 12, 2017
- Govt to Erase Reference Pricing from Honebuto Policy, though Proposal Still Alive
June 8, 2017
- Tweaking Likely for Honebuto Wording on Reference Pricing, Integration of Gx Price Bands
June 7, 2017
- Inject Intensive Resources for Healthy Lifespan Extension: Honebuto Draft
June 5, 2017
- Honebuto Policy to Incorporate Timeline for Drug Pricing Overhaul
June 2, 2017
REGULATORY
- LDP Panel Finalizes Honebuto Proposal on Preventive Care, Adds Obesity Focus
June 5, 2026
- Ex-GSK Japan Head Calls for End to "Obsolete" 14-Day Prescription Limit
June 5, 2026
- Trazenta Generic Outlook Remains Clouded as Court Upholds Treatment-Method Patents
June 4, 2026
- LDP Generic Caucus Wants Swift Disclosure of Company Indicator Ratings
June 4, 2026
- LDP Social Security Panel Pushes Greater Reward for Innovation: Honebuto Proposal
June 3, 2026
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…